Atlas Trials

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Clinical trial NCT00001683 · COMPLETED

Trial details

NCT number
NCT00001683
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
LymphomaMelanomaNeoplasm MetastasisRenal Cell Carcinoma
Start date
1997-10-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.